Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer TreatmentGlobeNewsWire • 08/08/23
Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking StatusGlobeNewsWire • 08/07/23
Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume GrowthGlobeNewsWire • 08/03/23
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk AssessmentGlobeNewsWire • 07/24/23
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing PlatformGlobeNewsWire • 06/12/23
Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023GlobeNewsWire • 06/01/23
Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad GeneticsGlobeNewsWire • 05/31/23
Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian CancerGlobeNewsWire • 05/24/23
Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance RangeGlobeNewsWire • 05/03/23